MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas

Neuro Oncol. 2022 Apr 1;24(4):665-667. doi: 10.1093/neuonc/noac014.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Astrocytoma* / drug therapy
  • Astrocytoma* / genetics
  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / genetics
  • DNA Methylation
  • DNA Modification Methylases / genetics
  • DNA Repair Enzymes / genetics
  • Glioblastoma* / drug therapy
  • Humans
  • Methylation
  • Temozolomide / therapeutic use
  • Tumor Suppressor Proteins / genetics

Substances

  • Antineoplastic Agents, Alkylating
  • Tumor Suppressor Proteins
  • DNA Modification Methylases
  • MGMT protein, human
  • DNA Repair Enzymes
  • Temozolomide